“This study, which included 419 postmenopausal women with low bone mass, showed that inhibiting sclerostin with romosozumab, a humanized monoclonal antibody targeted to sclerostin, induced large increases in bone-formation markers, decreased a bone-resorption marker, and increased bone mineral density when the drug was administered by means of subcutaneous injection at 1-month or 3-month intervals. Although dose-dependency was not formally tested, the larger doses that were administered monthly (140 mg or 210 mg) appeared to produce greater changes than the other regimens.” M.R. McClung and Others, Original Article, “Romosozumab in Postmenopausal Women with Low Bone Mineral Density”
Posted on: Thu, 30 Jan 2014 04:51:10 +0000
Trending Topics
Recently Viewed Topics
© 2015